Assessment of Some Bone Turnover in Chronic Kidney Disease Patients in Tikrit/Iraq
Main Article Content
Keywords
Kidney, Disease, Assessment, Group
Abstract
The present study aimed to assess some bone turnover in chronic kidney disease with and without hemodialysis. 50 individuals were involved in the study and divided into three groups; the first two groups were patients with chronic kidney disease (15 were with hemodialysis, and 15 were without hemodialysis), and the third group involved 20 healthy individuals as a control group. Some bone
turnovers like parathyroid hormone, vitamin D3, insulin-like growth factor-1, osteopontin, fibroblast growth factor-23, and calprotectin were analyzed using serum from all individuals. The serum concentration of parathyroid hormone was significantly lower (P>0.05) in chronic kidney disease with non-hemodialysis compared to chronic kidney disease with hemodialysis group and healthy individuals. While serum concentrations of vitamin D3, insulin-like growth factor, and osteopontin were significantly lower in both chronic kidney disease groups compared to healthy individuals. The serum concentration of fibroblast growth factor showed a non-significant difference (P<0.05) in both chronic kidney disease groups compared to healthy individuals. While serum concentration of calprotectin showed a significant increase (P>0.05) only in the chronic kidney disease without hemodialysis group compared to both other groups.
References
1. Evans M, Lewis RD, Morgan AR, Whyte MB, Hanif W, Bain SC, Davies S, Dashora U, Yousef Z, Patel DC, Strain WD. A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives. Advances in Therapy [Internet]. 2021 Nov 5 [cited 2022 Aug 6];39(1):33-43. Available from: https://doi.org/10.1007/s12325-021-01927-z
2. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, Hobbs FD. Global Prevalence of Chronic Kidney Disease –A Systematic Review and Meta-Analysis. PLOS ONE [Internet]. 2016 Jul 6 [cited 2022 Aug 6];11(7):e0158765.Available from:https://doi.org/10.1371/journal.pone.0158765
3. Fukagawa M, Komaba H, Onishi Y, Fukuhara S, Akizawa T, Kurokawa K. Mineral Metabolism Management in Hemodialysis Patients with
Secondary Hyperparathyroidism in Japan: Baseline Data from the MBD-5D. American Journal of Nephrology [Internet]. 2011 [cited
2022 Aug 6];33(5):427-37. Available from: https://doi.org/10.1159/000327654
4. Radeef M. Association between Allelic Variations of -174G/C Polymorphism of Interleukin-6 Gene and Chronic Kidney DiseaseMineral and Bone Disorder in Iraqi Patients. Baghdad Science Journal [Internet]. 2020 Dec 1 [cited 2022 Aug 6];17(4):1145. Available from: https://doi.org/10.21123/bsj.2020.17.4.1145
5. Gallieni M, De Luca N, Santoro D, Meneghel G, Formica M, Grandaliano G, Pizzarelli F, Cossu M, Segoloni G, Quintaliani G, Di Giulio S,
Pisani A, Malaguti M, Marseglia C, Oldrizzi L, Pacilio M, Conte G, Dal Canton A, Minutolo R. Management of CKD-MBD in non-dialysis
patients under regular nephrology care: a prospective multicenter study. Journal of Nephrology [Internet]. 2015 May 19 [cited 2022 Aug 6];29(1):71-8. Available from: https://doi.org/10.1007/s40620-015-0202-4
6. Teppala S, Shankar A, Sabanayagam C.Association between IGF-1 and chronic kidney disease among US adults. Clinical and Experimental Nephrology [Internet]. 2010 Jun 22 [cited 2022 Aug 6];14(5):440-4. Available from: https://doi.org/10.1007/s10157-010-0307-y
7. Nishi H, Uchida K, Saito M, Yamanaka D, Nagata H, Tomoshige H, Miyata I, Ito K, Toyoshima Y, Takahashi SI, Hakuno F, Takenaka A. Essential Amino Acid Intake Is Required for Sustaining Serum Insulin-like Growth Factor-I Levels but Is Not Necessarily Needed for Body Growth. Cells [Internet]. 2022 May 2 [cited 2022 Aug 6];11(9):1523. Available from: https://doi.org/10.3390/cells11091523.
8. Shamsulddin HH, Salih LA, Eleiwe SA. Relationship Between Osteopontin Biochemical Parameters and BMD Status in Iraqi Postmenopausal Women with Osteoporosis. Iraqi Journal of Science [Internet]. 2020 Oct 28 [cited 2022 Aug 6]:2494-503. Available from: https://doi.org/10.24996/ijs.2020.61.10.6
9. Ameen ZA, Ali S. Effects of Aldosterone, Osteoprotegerin and Fibroblast Growth Factor-23 and Some Biochemical Markers in Chronic Kidney Disease Patients' (Stage II-IV) among Patients with or without Cardiovascular Events. Iraqi Journal of Pharmaceutical Sciences ( PISSN: 1683 - 3597 , E-ISSN : 2521 - 3512) [Internet]. 2018 Dec 7 [cited 2022 Aug 6]:150-8. Available from: https://doi.org/10.31351/vol27iss2pp150-158
10. Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis. JAMA [Internet]. 2016 Aug 16 [cited 2022 Aug 6];316(7):722. Available from: https://doi.org/10.1001/jama.2016.11136
11. Bover J, Cozzolino M. Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin
D receptor activation. Kidney International Supplements [Internet]. 2011 Sep [cited 2022 Aug 6];1(4):122-9. Available from: https://doi.org/10.1038/kisup.2011.28
12. Kritmetapak K, Pongchaiyakul C. Parathyroid Hormone Measurement in Chronic Kidney Disease: From Basics to Clinical Implications.
International Journal of Nephrology [Internet]. 2019 Sep 17 [cited 2022 Aug 6];2019:1-9. Available from: https://doi.org/10.1155/2019/5496710
13. Dawson-Hughes B, Wang J, Barger K, BischoffFerrari HA, Sempos CT, Durazo-Arvizu RA, Ceglia L. Intra-trial Mean 25(OH)D and PTH
Levels and Risk of Falling in Older Men and Women in the Boston STOP IT Trial. The Journal of Clinical Endocrinology & Metabolism [Internet]. 2022 Jan 12 [cited 2022 Aug 6];107(5):e1932-e1937. Available from: https://doi.org/10.1210/clinem/dgac012.
14. Franca Gois P, Wolley M, Ranganathan D, Seguro A. Vitamin D Deficiency in Chronic Kidney Disease: Recent Evidence and Controversies. International Journal of Environmental Research and Public Health [Internet]. 2018 Aug 17 [cited 2022 Aug 6];15(8):1773. Available
from: https://doi.org/10.3390/ijerph15081773
15. Gois P, Ferreira D, Olenski S, Seguro A. Vitamin D and Infectious Diseases: Simple Bystander or Contributing Factor? Nutrients [Internet]. 2017 Jun 24 [cited 2022 Aug 6];9(7):651. Available from: https://doi.org/10.3390/nu9070651
16. Wang J, Zhou J, Robertson G, Lee V. Vitamin D in Vascular Calcification: A Double-Edged Sword? Nutrients [Internet]. 2018 May 22 [cited
2022 Aug 6];10(5):652. Available from: https://doi.org/10.3390/nu10050652
17. Naveh-Many T, Volovelsky O. Parathyroid Cell Proliferation in Secondary Hyperparathyroidism of Chronic Kidney Disease. International Journal of Molecular Sciences [Internet]. 2020 Jun 18 [cited 2022 Aug 6];21(12):4332. Available from: https://doi.org/10.3390/ijms21124332
18. Goel N, Pokharna H, Abramowitz MK, Gnanasekaran I. Mineral and Bone Metabolism Disorders in Minority Incident ESRD Patients in
an Inner-City Hemodialysis Unit. Einstein Journal of Biology and Medicine [Internet]. 2016 Mar 2 [cited 2022 Aug 6];30(1&2):16. Available
from: https://doi.org/10.23861/ejbm201530634
19. Adhikary LP, Pokhrel A, Yadava SK, Khadka D, Thakur R. Relation between Serum Intact Parathyroid Hormone Level and Hematocrit in Chronic Kidney Disease Patients. Kathmandu University Medical Journal [Internet]. 2017 Feb 26 [cited 2022 Aug 6];13(3):220-3. Available from: https://doi.org/10.3126/kumj.v13i3.16811
20. Underbjerg L, Sikjaer T, Rejnmark L. LongTerm Complications in Patients With Hypoparathyroidism Evaluated by Biochemical Findings: A Case-Control Study. Journal of Bone and Mineral Research [Internet]. 2018 Feb 14 [cited 2022 Aug 6];33(5):822-31. Available from: https://doi.org/10.1002/jbmr.3368
21. Ghelichi-Ghojogh M, Fararouei M, Seif M, Pakfetrat M. Chronic kidney disease and its health-related factors: a case-control study. BMC
Nephrology [Internet]. 2022 Jan 10 [cited 2022 Aug 6];23(1). Available from: https://doi.org/10.1186/s12882-021-02655-w.
22. Al-Khateeb M. The role of Leptin and Insulin like Growth factor-1 in patients with end stage renal disease under haemodialysis (pre & post
dialysis). Mustansiriya Medical Journal [Internet]. 2013 Apr 14 [cited 2022 Aug 6] 12(1), 53. Available from: https://www.iasj.net/iasj/article/75606.
23. Chen Z, Nilsson E, Lindholm B, Heimbürger O, Barany P, Stenvinkel P, Qureshi AR, Chen J. Low plasma insulin-like growth factor-1 associates with increased mortality in chronic kidney disease patients with reduced muscle strength. Journal of Renal Nutrition [Internet].
2022 Jul [cited 2022 Aug 6]. Available from: https://doi.org/10.1053/j.jrn.2022.06.008.
24. Haffner D, Grund A, Leifheit-Nestler M. Renal effects of growth hormone in health and in kidney disease. Pediatric Nephrology [Internet]. 2021 Jun 18 [cited 2022 Aug 6]. Available from: https://doi.org/10.1007/s00467-021-05097-6
25. Vasilkova VN, Mokhort TV, Pchelin IY, Bayrasheva VK, Naumenko EP, Korotaeva LE, Filiptsova NA. Association between serum
insulin like growth factor-1 (IGF-1) and insulinlike growth factor-binding protein-3 levels and chronic kidney disease in diabetic patients.
Journal of Renal Injury Prevention [Internet]. 2020 Mar 10 [cited 2022 Aug 6];10(1):e05-e05. Available from: https://doi.org/10.34172/jrip.2021.05
26. Dichtel LE, Cordoba-Chacon J, Kineman RD. Growth hormone and insulin-like growth factor I regulation of nonalcoholic fatty liver disease. The Journal of Clinical Endocrinology & Metabolism [Internet]. 2022 Feb 16 [cited 2022 Aug 6]. Available from: https://doi.org/10.1210/clinem/dgac088
27. Gao ST, Lv ZT, Zhou CK, Mao C, Sheng WB. Association between IGF-1 polymorphisms and risk of osteoporosis in Chinese population: a
meta-analysis. BMC Musculoskeletal Disorders [Internet]. 2018 May 10 [cited 2022 Aug 6];19(1). Available from: https://doi.org/10.1186/s12891-018-2066-y
28. Racine HL, Serrat MA. The Actions of IGF-1 in the Growth Plate and Its Role in Postnatal Bone Elongation. Current Osteoporosis Reports
[Internet]. 2020 May 15 [cited 2022 Aug 6];18(3):210-27. Available from: https://doi.org/10.1007/s11914-020-00570-x
29. Durá-Travé T, Gallinas-Victoriano F. Vitamin D and Parathyroid Hormone during Growth Hormone Treatment. Children [Internet]. 2022 May 15 [cited 2022 Aug 6];9(5):725. Available from: https://doi.org/10.3390/children9050725
30. Kaleta B. The role of osteopontin in kidney diseases. Inflammation Research [Internet]. 2018 Nov 19 [cited 2022 Aug 6];68(2):93-102.
Available from: https://doi.org/10.1007/s00011-018-1200-5
31. Abdalrhim AD, Marroush TS, Austin EE, Gersh BJ, Solak N, Rizvi SA, Bailey KR, Kullo IJ. Plasma Osteopontin Levels and Adverse Cardiovascular Outcomes in the PEACE Trial. PLOS ONE [Internet]. 2016 Jun 10 [cited 2022 Aug 6];11(6):e0156965. Available from: https://doi.org/10.1371/journal.pone.0156965
32. Cheng Y, Li Y, Scherer N, GrundnerCulemann F, Lehtimäki T, Mishra BH, Raitakari OT, Nauck M, Eckardt KU, Sekula P, Schultheiss UT. Genetics of osteopontin in patients with chronic kidney disease: The German Chronic Kidney Disease study. PLOS Genetics [Internet]. 2022 Apr 6 [cited 2022 Aug 6];18(4):e1010139. Available from: https://doi.org/10.1371/journal.pgen.1010139
33. Barreto DV, Lenglet A, Liabeuf S, Kretschmer A, Barreto FC, Nollet A, Slama M, Choukroun G, Brazier M, Massy Z. Prognostic Implication of Plasma Osteopontin Levels in Patients with Chronic Kidney Disease. Nephron Clinical Practice [Internet]. 2010 Nov 12 [cited 2022 Aug 6];117(4):363-72. Available from: https://doi.org/10.1159/000321520
34. Scialla JJ, Kao WH, Crainiceanu C, Sozio SM, Oberai PC, Shafi T, Coresh J, Powe NR, Plantinga LC, Jaar BG, Parekh RS. Biomarkers of Vascular Calcification and Mortality in Patients with ESRD. Clinical Journal of the American Society of Nephrology [Internet]. 2014 Jan 23 [cited 2022 Aug 6];9(4):745-55. Available from: https://doi.org/10.2215/cjn.05450513
35. Wilson SR, Peters C, Saftig P, Brömme D. Cathepsin K Activity-dependent Regulation of Osteoclast Actin Ring Formation and Bone Resorption. Journal of Biological Chemistry [Internet]. 2008 Nov 21 [cited 2022 Aug 6];284(4):2584-92. Available from: https://doi.org/10.1074/jbc.m805280200
36. Lorenzen JM, Hafer C, Faulhaber-Walter R, Kumpers P, Kielstein JT, Haller H, Fliser D. Osteopontin predicts survival in critically ill patients with acute kidney injury. Nephrology Dialysis Transplantation [Internet]. 2010 Aug 23 [cited 2022 Aug 6];26(2):531-7. Available from: https://doi.org/10.1093/ndt/gfq498
37. Nawar AM, Elhendy YA, Nabil M, Sami MM, Salah AM, Allam HM. The Relationship between Serum Osteopontin level and Parameters of
Chronic Kidney Disease – Mineral Bone Disease in Patients on Regular Hemodialysis. The Egyptian Journal of Hospital Medicine [Internet].
2022 Jan 1 [cited 2022 Aug 6];86(1):499-501. Available from: https://doi.org/10.21608/ejhm.2022.213805
38. Guo YC, Yuan Q. Fibroblast growth factor 23 and bone mineralisation. International Journal of Oral Science [Internet]. 2015 Feb 6 [cited 2022 Aug 6];7(1):8-13. Available from: https://doi.org/10.1038/ijos.2015.1
39. Portale AA, Wolf MS, Messinger S, Perwad F, Jüppner H, Warady BA, Furth SL, Salusky IB. Fibroblast Growth Factor 23 and Risk of CKD
Progression in Children. Clinical Journal of the American Society of Nephrology [Internet]. 2016 Aug 25 [cited 2022 Aug 6];11(11):1989-98.
Available from: https://doi.org/10.2215/cjn.02110216
40. Salanova Villanueva L, Sánchez González C, Sánchez Tomero JA, Aguilera A, Ortega Junco E. Bone mineral disorder in chronic kidney
disease: Klotho and FGF23; cardiovascular implications. Nefrología (English Edition) [Internet]. 2016 Jul [cited 2022 Aug 6];36(4):368-75. Available from: https://doi.org/10.1016/j.nefroe.2016.08.001
41. Kazancioğlu R. Risk factors for chronic kidney disease: an update. Kidney International Supplements [Internet]. 2013 Dec [cited 2022
Aug 6];3(4):368-71. Available from: https://doi.org/10.1038/kisup.2013.79
42. López I, Rodríguez-Ortiz ME, Almadén Y, Guerrero F, Oca AM, Pineda C, Shalhoub V, Rodríguez M, Aguilera-Tejero E. Direct and
indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney International [Internet]. 2011 Sep
[cited 2022 Aug 6];80(5):475-82. Available from: https://doi.org/10.1038/ki.2011.107
43. Seibert FS, Pagonas N, Arndt R, Heller F, Dragun D, Persson P, Schmidt-Ott K, Zidek W, Westhoff TH. Calprotectin and neutrophil gelatinase-associated lipocalin in the differentiation of pre-renal and intrinsic acute kidney injury. Acta Physiologica [Internet]. 2013 Feb 14 [cited 2022 Aug 6];207(4):700-8. Available from: https://doi.org/10.1111/apha.12064
44. Sevik G, Barutcu Atas D, Ilgin C, Asicioglu E, Tuglular S, Velioglu A. Peritoneal calprotectin level in peritoneal dialysis patients. Seminars in
Dialysis [Internet]. 2022 Apr 19 [cited 2022 Aug 6]. Available from: https://doi.org/10.1111/sdi.13082
45. Heller F, Frischmann S, Grünbaum M, Zidek W, Westhoff TH. Urinary Calprotectin and the Distinction between Prerenal and Intrinsic Acute
Kidney Injury. Clinical Journal of the American Society of Nephrology [Internet]. 2011 Sep 1 [cited 2022 Aug 6];6(10):2347-55. Available from: https://doi.org/10.2215/cjn.02490311
46. Kanki T, Kuwabara T, Morinaga J, Fukami H, Umemoto S, Fujimoto D, Mizumoto T, Hayata M, Kakizoe Y, Izumi Y, Tajiri S, Tajiri T, Kitamura K, Mukoyama M. The predictive role of serum calprotectin on mortality in hemodialysis patients with high phosphoremia. BMC Nephrology [Internet]. 2020 May 4 [cited 2022 Aug 6];21(1). Available from: https://doi.org/10.1186/s12882-020-01812-x
47. Smith ER, Ford ML, Tomlinson LA, Rajkumar C, McMahon LP, Holt SG. Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrology Dialysis Transplantation [Internet]. 2012 May [cited 2022 Aug 6];27(5):1957-66. Available from: https://doi.org/10.1093/ndt/gfr609
48. Kuro-o M. A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease. Kidney International Supplements
[Internet]. 2013 Dec [cited 2022 Aug 6];3(5):420-6. Available from: https://doi.org/10.1038/kisup.2013.88
49. Kuwabara T, Mori K, Kasahara M, Yokoi H, Imamaki H, Ishii A, Koga K, Sugawara A, Yasuno S, Ueshima K, Morikawa T, Konishi Y,
Imanishi M, Nishiyama A, Nakao K, Mukoyama M. Predictive Significance of Kidney Myeloid-Related Protein 8 Expression in Patients
with Obesity- or Type 2 Diabetes-Associated Kidney Diseases. PLoS ONE [Internet]. 2014 Feb 18 [cited 2022 Aug 6];9(2):e88942. Available
from: https://doi.org/10.1371/journal.pone.0088942
2. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, Hobbs FD. Global Prevalence of Chronic Kidney Disease –A Systematic Review and Meta-Analysis. PLOS ONE [Internet]. 2016 Jul 6 [cited 2022 Aug 6];11(7):e0158765.Available from:https://doi.org/10.1371/journal.pone.0158765
3. Fukagawa M, Komaba H, Onishi Y, Fukuhara S, Akizawa T, Kurokawa K. Mineral Metabolism Management in Hemodialysis Patients with
Secondary Hyperparathyroidism in Japan: Baseline Data from the MBD-5D. American Journal of Nephrology [Internet]. 2011 [cited
2022 Aug 6];33(5):427-37. Available from: https://doi.org/10.1159/000327654
4. Radeef M. Association between Allelic Variations of -174G/C Polymorphism of Interleukin-6 Gene and Chronic Kidney DiseaseMineral and Bone Disorder in Iraqi Patients. Baghdad Science Journal [Internet]. 2020 Dec 1 [cited 2022 Aug 6];17(4):1145. Available from: https://doi.org/10.21123/bsj.2020.17.4.1145
5. Gallieni M, De Luca N, Santoro D, Meneghel G, Formica M, Grandaliano G, Pizzarelli F, Cossu M, Segoloni G, Quintaliani G, Di Giulio S,
Pisani A, Malaguti M, Marseglia C, Oldrizzi L, Pacilio M, Conte G, Dal Canton A, Minutolo R. Management of CKD-MBD in non-dialysis
patients under regular nephrology care: a prospective multicenter study. Journal of Nephrology [Internet]. 2015 May 19 [cited 2022 Aug 6];29(1):71-8. Available from: https://doi.org/10.1007/s40620-015-0202-4
6. Teppala S, Shankar A, Sabanayagam C.Association between IGF-1 and chronic kidney disease among US adults. Clinical and Experimental Nephrology [Internet]. 2010 Jun 22 [cited 2022 Aug 6];14(5):440-4. Available from: https://doi.org/10.1007/s10157-010-0307-y
7. Nishi H, Uchida K, Saito M, Yamanaka D, Nagata H, Tomoshige H, Miyata I, Ito K, Toyoshima Y, Takahashi SI, Hakuno F, Takenaka A. Essential Amino Acid Intake Is Required for Sustaining Serum Insulin-like Growth Factor-I Levels but Is Not Necessarily Needed for Body Growth. Cells [Internet]. 2022 May 2 [cited 2022 Aug 6];11(9):1523. Available from: https://doi.org/10.3390/cells11091523.
8. Shamsulddin HH, Salih LA, Eleiwe SA. Relationship Between Osteopontin Biochemical Parameters and BMD Status in Iraqi Postmenopausal Women with Osteoporosis. Iraqi Journal of Science [Internet]. 2020 Oct 28 [cited 2022 Aug 6]:2494-503. Available from: https://doi.org/10.24996/ijs.2020.61.10.6
9. Ameen ZA, Ali S. Effects of Aldosterone, Osteoprotegerin and Fibroblast Growth Factor-23 and Some Biochemical Markers in Chronic Kidney Disease Patients' (Stage II-IV) among Patients with or without Cardiovascular Events. Iraqi Journal of Pharmaceutical Sciences ( PISSN: 1683 - 3597 , E-ISSN : 2521 - 3512) [Internet]. 2018 Dec 7 [cited 2022 Aug 6]:150-8. Available from: https://doi.org/10.31351/vol27iss2pp150-158
10. Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis. JAMA [Internet]. 2016 Aug 16 [cited 2022 Aug 6];316(7):722. Available from: https://doi.org/10.1001/jama.2016.11136
11. Bover J, Cozzolino M. Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin
D receptor activation. Kidney International Supplements [Internet]. 2011 Sep [cited 2022 Aug 6];1(4):122-9. Available from: https://doi.org/10.1038/kisup.2011.28
12. Kritmetapak K, Pongchaiyakul C. Parathyroid Hormone Measurement in Chronic Kidney Disease: From Basics to Clinical Implications.
International Journal of Nephrology [Internet]. 2019 Sep 17 [cited 2022 Aug 6];2019:1-9. Available from: https://doi.org/10.1155/2019/5496710
13. Dawson-Hughes B, Wang J, Barger K, BischoffFerrari HA, Sempos CT, Durazo-Arvizu RA, Ceglia L. Intra-trial Mean 25(OH)D and PTH
Levels and Risk of Falling in Older Men and Women in the Boston STOP IT Trial. The Journal of Clinical Endocrinology & Metabolism [Internet]. 2022 Jan 12 [cited 2022 Aug 6];107(5):e1932-e1937. Available from: https://doi.org/10.1210/clinem/dgac012.
14. Franca Gois P, Wolley M, Ranganathan D, Seguro A. Vitamin D Deficiency in Chronic Kidney Disease: Recent Evidence and Controversies. International Journal of Environmental Research and Public Health [Internet]. 2018 Aug 17 [cited 2022 Aug 6];15(8):1773. Available
from: https://doi.org/10.3390/ijerph15081773
15. Gois P, Ferreira D, Olenski S, Seguro A. Vitamin D and Infectious Diseases: Simple Bystander or Contributing Factor? Nutrients [Internet]. 2017 Jun 24 [cited 2022 Aug 6];9(7):651. Available from: https://doi.org/10.3390/nu9070651
16. Wang J, Zhou J, Robertson G, Lee V. Vitamin D in Vascular Calcification: A Double-Edged Sword? Nutrients [Internet]. 2018 May 22 [cited
2022 Aug 6];10(5):652. Available from: https://doi.org/10.3390/nu10050652
17. Naveh-Many T, Volovelsky O. Parathyroid Cell Proliferation in Secondary Hyperparathyroidism of Chronic Kidney Disease. International Journal of Molecular Sciences [Internet]. 2020 Jun 18 [cited 2022 Aug 6];21(12):4332. Available from: https://doi.org/10.3390/ijms21124332
18. Goel N, Pokharna H, Abramowitz MK, Gnanasekaran I. Mineral and Bone Metabolism Disorders in Minority Incident ESRD Patients in
an Inner-City Hemodialysis Unit. Einstein Journal of Biology and Medicine [Internet]. 2016 Mar 2 [cited 2022 Aug 6];30(1&2):16. Available
from: https://doi.org/10.23861/ejbm201530634
19. Adhikary LP, Pokhrel A, Yadava SK, Khadka D, Thakur R. Relation between Serum Intact Parathyroid Hormone Level and Hematocrit in Chronic Kidney Disease Patients. Kathmandu University Medical Journal [Internet]. 2017 Feb 26 [cited 2022 Aug 6];13(3):220-3. Available from: https://doi.org/10.3126/kumj.v13i3.16811
20. Underbjerg L, Sikjaer T, Rejnmark L. LongTerm Complications in Patients With Hypoparathyroidism Evaluated by Biochemical Findings: A Case-Control Study. Journal of Bone and Mineral Research [Internet]. 2018 Feb 14 [cited 2022 Aug 6];33(5):822-31. Available from: https://doi.org/10.1002/jbmr.3368
21. Ghelichi-Ghojogh M, Fararouei M, Seif M, Pakfetrat M. Chronic kidney disease and its health-related factors: a case-control study. BMC
Nephrology [Internet]. 2022 Jan 10 [cited 2022 Aug 6];23(1). Available from: https://doi.org/10.1186/s12882-021-02655-w.
22. Al-Khateeb M. The role of Leptin and Insulin like Growth factor-1 in patients with end stage renal disease under haemodialysis (pre & post
dialysis). Mustansiriya Medical Journal [Internet]. 2013 Apr 14 [cited 2022 Aug 6] 12(1), 53. Available from: https://www.iasj.net/iasj/article/75606.
23. Chen Z, Nilsson E, Lindholm B, Heimbürger O, Barany P, Stenvinkel P, Qureshi AR, Chen J. Low plasma insulin-like growth factor-1 associates with increased mortality in chronic kidney disease patients with reduced muscle strength. Journal of Renal Nutrition [Internet].
2022 Jul [cited 2022 Aug 6]. Available from: https://doi.org/10.1053/j.jrn.2022.06.008.
24. Haffner D, Grund A, Leifheit-Nestler M. Renal effects of growth hormone in health and in kidney disease. Pediatric Nephrology [Internet]. 2021 Jun 18 [cited 2022 Aug 6]. Available from: https://doi.org/10.1007/s00467-021-05097-6
25. Vasilkova VN, Mokhort TV, Pchelin IY, Bayrasheva VK, Naumenko EP, Korotaeva LE, Filiptsova NA. Association between serum
insulin like growth factor-1 (IGF-1) and insulinlike growth factor-binding protein-3 levels and chronic kidney disease in diabetic patients.
Journal of Renal Injury Prevention [Internet]. 2020 Mar 10 [cited 2022 Aug 6];10(1):e05-e05. Available from: https://doi.org/10.34172/jrip.2021.05
26. Dichtel LE, Cordoba-Chacon J, Kineman RD. Growth hormone and insulin-like growth factor I regulation of nonalcoholic fatty liver disease. The Journal of Clinical Endocrinology & Metabolism [Internet]. 2022 Feb 16 [cited 2022 Aug 6]. Available from: https://doi.org/10.1210/clinem/dgac088
27. Gao ST, Lv ZT, Zhou CK, Mao C, Sheng WB. Association between IGF-1 polymorphisms and risk of osteoporosis in Chinese population: a
meta-analysis. BMC Musculoskeletal Disorders [Internet]. 2018 May 10 [cited 2022 Aug 6];19(1). Available from: https://doi.org/10.1186/s12891-018-2066-y
28. Racine HL, Serrat MA. The Actions of IGF-1 in the Growth Plate and Its Role in Postnatal Bone Elongation. Current Osteoporosis Reports
[Internet]. 2020 May 15 [cited 2022 Aug 6];18(3):210-27. Available from: https://doi.org/10.1007/s11914-020-00570-x
29. Durá-Travé T, Gallinas-Victoriano F. Vitamin D and Parathyroid Hormone during Growth Hormone Treatment. Children [Internet]. 2022 May 15 [cited 2022 Aug 6];9(5):725. Available from: https://doi.org/10.3390/children9050725
30. Kaleta B. The role of osteopontin in kidney diseases. Inflammation Research [Internet]. 2018 Nov 19 [cited 2022 Aug 6];68(2):93-102.
Available from: https://doi.org/10.1007/s00011-018-1200-5
31. Abdalrhim AD, Marroush TS, Austin EE, Gersh BJ, Solak N, Rizvi SA, Bailey KR, Kullo IJ. Plasma Osteopontin Levels and Adverse Cardiovascular Outcomes in the PEACE Trial. PLOS ONE [Internet]. 2016 Jun 10 [cited 2022 Aug 6];11(6):e0156965. Available from: https://doi.org/10.1371/journal.pone.0156965
32. Cheng Y, Li Y, Scherer N, GrundnerCulemann F, Lehtimäki T, Mishra BH, Raitakari OT, Nauck M, Eckardt KU, Sekula P, Schultheiss UT. Genetics of osteopontin in patients with chronic kidney disease: The German Chronic Kidney Disease study. PLOS Genetics [Internet]. 2022 Apr 6 [cited 2022 Aug 6];18(4):e1010139. Available from: https://doi.org/10.1371/journal.pgen.1010139
33. Barreto DV, Lenglet A, Liabeuf S, Kretschmer A, Barreto FC, Nollet A, Slama M, Choukroun G, Brazier M, Massy Z. Prognostic Implication of Plasma Osteopontin Levels in Patients with Chronic Kidney Disease. Nephron Clinical Practice [Internet]. 2010 Nov 12 [cited 2022 Aug 6];117(4):363-72. Available from: https://doi.org/10.1159/000321520
34. Scialla JJ, Kao WH, Crainiceanu C, Sozio SM, Oberai PC, Shafi T, Coresh J, Powe NR, Plantinga LC, Jaar BG, Parekh RS. Biomarkers of Vascular Calcification and Mortality in Patients with ESRD. Clinical Journal of the American Society of Nephrology [Internet]. 2014 Jan 23 [cited 2022 Aug 6];9(4):745-55. Available from: https://doi.org/10.2215/cjn.05450513
35. Wilson SR, Peters C, Saftig P, Brömme D. Cathepsin K Activity-dependent Regulation of Osteoclast Actin Ring Formation and Bone Resorption. Journal of Biological Chemistry [Internet]. 2008 Nov 21 [cited 2022 Aug 6];284(4):2584-92. Available from: https://doi.org/10.1074/jbc.m805280200
36. Lorenzen JM, Hafer C, Faulhaber-Walter R, Kumpers P, Kielstein JT, Haller H, Fliser D. Osteopontin predicts survival in critically ill patients with acute kidney injury. Nephrology Dialysis Transplantation [Internet]. 2010 Aug 23 [cited 2022 Aug 6];26(2):531-7. Available from: https://doi.org/10.1093/ndt/gfq498
37. Nawar AM, Elhendy YA, Nabil M, Sami MM, Salah AM, Allam HM. The Relationship between Serum Osteopontin level and Parameters of
Chronic Kidney Disease – Mineral Bone Disease in Patients on Regular Hemodialysis. The Egyptian Journal of Hospital Medicine [Internet].
2022 Jan 1 [cited 2022 Aug 6];86(1):499-501. Available from: https://doi.org/10.21608/ejhm.2022.213805
38. Guo YC, Yuan Q. Fibroblast growth factor 23 and bone mineralisation. International Journal of Oral Science [Internet]. 2015 Feb 6 [cited 2022 Aug 6];7(1):8-13. Available from: https://doi.org/10.1038/ijos.2015.1
39. Portale AA, Wolf MS, Messinger S, Perwad F, Jüppner H, Warady BA, Furth SL, Salusky IB. Fibroblast Growth Factor 23 and Risk of CKD
Progression in Children. Clinical Journal of the American Society of Nephrology [Internet]. 2016 Aug 25 [cited 2022 Aug 6];11(11):1989-98.
Available from: https://doi.org/10.2215/cjn.02110216
40. Salanova Villanueva L, Sánchez González C, Sánchez Tomero JA, Aguilera A, Ortega Junco E. Bone mineral disorder in chronic kidney
disease: Klotho and FGF23; cardiovascular implications. Nefrología (English Edition) [Internet]. 2016 Jul [cited 2022 Aug 6];36(4):368-75. Available from: https://doi.org/10.1016/j.nefroe.2016.08.001
41. Kazancioğlu R. Risk factors for chronic kidney disease: an update. Kidney International Supplements [Internet]. 2013 Dec [cited 2022
Aug 6];3(4):368-71. Available from: https://doi.org/10.1038/kisup.2013.79
42. López I, Rodríguez-Ortiz ME, Almadén Y, Guerrero F, Oca AM, Pineda C, Shalhoub V, Rodríguez M, Aguilera-Tejero E. Direct and
indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney International [Internet]. 2011 Sep
[cited 2022 Aug 6];80(5):475-82. Available from: https://doi.org/10.1038/ki.2011.107
43. Seibert FS, Pagonas N, Arndt R, Heller F, Dragun D, Persson P, Schmidt-Ott K, Zidek W, Westhoff TH. Calprotectin and neutrophil gelatinase-associated lipocalin in the differentiation of pre-renal and intrinsic acute kidney injury. Acta Physiologica [Internet]. 2013 Feb 14 [cited 2022 Aug 6];207(4):700-8. Available from: https://doi.org/10.1111/apha.12064
44. Sevik G, Barutcu Atas D, Ilgin C, Asicioglu E, Tuglular S, Velioglu A. Peritoneal calprotectin level in peritoneal dialysis patients. Seminars in
Dialysis [Internet]. 2022 Apr 19 [cited 2022 Aug 6]. Available from: https://doi.org/10.1111/sdi.13082
45. Heller F, Frischmann S, Grünbaum M, Zidek W, Westhoff TH. Urinary Calprotectin and the Distinction between Prerenal and Intrinsic Acute
Kidney Injury. Clinical Journal of the American Society of Nephrology [Internet]. 2011 Sep 1 [cited 2022 Aug 6];6(10):2347-55. Available from: https://doi.org/10.2215/cjn.02490311
46. Kanki T, Kuwabara T, Morinaga J, Fukami H, Umemoto S, Fujimoto D, Mizumoto T, Hayata M, Kakizoe Y, Izumi Y, Tajiri S, Tajiri T, Kitamura K, Mukoyama M. The predictive role of serum calprotectin on mortality in hemodialysis patients with high phosphoremia. BMC Nephrology [Internet]. 2020 May 4 [cited 2022 Aug 6];21(1). Available from: https://doi.org/10.1186/s12882-020-01812-x
47. Smith ER, Ford ML, Tomlinson LA, Rajkumar C, McMahon LP, Holt SG. Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrology Dialysis Transplantation [Internet]. 2012 May [cited 2022 Aug 6];27(5):1957-66. Available from: https://doi.org/10.1093/ndt/gfr609
48. Kuro-o M. A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease. Kidney International Supplements
[Internet]. 2013 Dec [cited 2022 Aug 6];3(5):420-6. Available from: https://doi.org/10.1038/kisup.2013.88
49. Kuwabara T, Mori K, Kasahara M, Yokoi H, Imamaki H, Ishii A, Koga K, Sugawara A, Yasuno S, Ueshima K, Morikawa T, Konishi Y,
Imanishi M, Nishiyama A, Nakao K, Mukoyama M. Predictive Significance of Kidney Myeloid-Related Protein 8 Expression in Patients
with Obesity- or Type 2 Diabetes-Associated Kidney Diseases. PLoS ONE [Internet]. 2014 Feb 18 [cited 2022 Aug 6];9(2):e88942. Available
from: https://doi.org/10.1371/journal.pone.0088942
Article Sidebar
Published
Mar 13, 2023
Article Details
How to Cite
Manar Muyasser Muhammed, & Firas Faris Rija. (2023). Assessment of Some Bone Turnover in Chronic Kidney Disease Patients in Tikrit/Iraq. Journal of Population Therapeutics and Clinical Pharmacology, 30(3), 462-470. https://doi.org/10.47750/jptcp.2023.30.03.048
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Manar Muyasser Muhammed, & Firas Faris Rija. (2023). Assessment of Some Bone Turnover in Chronic Kidney Disease Patients in Tikrit/Iraq. Journal of Population Therapeutics and Clinical Pharmacology, 30(3), 462-470. https://doi.org/10.47750/jptcp.2023.30.03.048